Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. - Wikidata - wikimedia - TriplyDB

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

http://www.wikidata.org/entity/Q40395042

about

Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)Antifungal susceptibility testing: current role from the clinical laboratory perspective Recent developments in the management of invasive fungal infections in patients with oncohematological diseases Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model.Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting.Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Canadian clinical practice guidelines for invasive candidiasis in adults.The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.Treatment options in Invasive Aspergillosis.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: what is available in 2010?Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project.How to treat fungal infections in ICU patients.Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy--retrospective analysis of changes over 3 yr in a German hospital.Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis.The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis.Use of antifungal drugs in hematology Neonatal fungal infections: when to treat?Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies Invasive fungal infections in acute leukemia.Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis.The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model.Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia.

P2860

Q24187699-8E6FACE7-2F69-4EB9-BFDD-9F099D28FA17 Q24239978-038A9DF6-B905-4FA2-80E5-151FBF73CFE2 Q26778187-0AAC1648-DC32-458F-BD4B-6D079E5C10FA Q26824260-06D9B486-7D4E-45DC-986E-8BE7CA5050AB Q26825753-B4AF878A-200F-43E7-A687-2346DC8132B4 Q26862478-FF004B05-F784-4711-925F-EEAF99A10478 Q28077381-5C8E5F13-35BA-4F10-AEE8-60541C85A747 Q28080147-7B24C008-FB82-4B18-A45F-C119CB3215D8 Q31120454-2E7751DC-B814-4251-86EB-44F6D599F322 Q33572014-736E7834-9561-416B-A571-8CF147F16047 Q33712955-AF762E93-6E73-4427-A93B-E8EBA18AF461 Q34151170-774470ED-ABC0-451B-92D5-EB85D380850F Q34237335-77079526-C67C-4D42-BD09-1DEB9C545306 Q34290097-5FC30D1B-2CBE-47E1-A553-F498E7E4EE9E Q34357504-2AFB2525-D68C-450E-9130-1D59715153DF Q34532546-6767FBFD-1C0B-4F18-A02C-B7D7851C3454 Q34543097-DB676955-5B62-4EEB-8972-9A34E3CFF16B Q34667166-27F6C3A3-DC21-46A8-9C54-70919E789412 Q35010346-F9BBD703-D798-4F51-A921-A66E8FCC34A9 Q35019920-8AA4EEF2-294E-4322-91A8-3907D54DC5FA Q35033597-84374869-5DC4-46FA-86F7-BA775910F110 Q35193749-57810325-CEF0-4FA9-9929-224F749342E3 Q35568846-5181629F-A372-458A-91C8-DC5CD516D916 Q35700698-5850E3CA-2A7C-4712-B9CF-7791BA118CFB Q35756513-C66CC84B-E920-413C-9661-C266404F6890 Q35794484-AAD1A9BA-BEF0-4D8A-BCAE-9A54DDCF165B Q35794490-DD1FC2C5-907B-472A-A024-C5BC2FD52B63 Q36049420-4031B325-E9B1-4A0C-B43D-50CD3D3D6D81 Q36264982-4B7AE36E-81EA-4BAE-A25F-5061A53D94F4 Q36364856-917BC22F-BD5F-4913-92F2-AF0C94049956 Q36440830-C6473AFE-EA10-4DF2-B7D1-53680C557F45 Q36456366-AF01400A-0EA3-4FE9-882D-4304D67FAC72 Q36584898-09F2FEAF-1B35-4127-93EB-A49A0201B6D8 Q36612597-5B2301D0-8A47-4413-BA50-A25841F7FFF6 Q36620870-FF56083C-D24C-4B3C-9D78-B12F13B852F8 Q36630700-472B76BE-67E7-4AFE-9D43-66AF7DD78442 Q36734965-B5C60431-056E-4C18-84C4-851931417384 Q36851160-48D5F554-311C-4F5B-82F1-74D783345281 Q37220711-097FD0DF-38ED-4A9C-96F8-98D925182856 Q37263911-90158380-CF78-4BA4-A43E-E6ABB5E4F417

P2860

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

http://www.wikidata.org/entity/Q40395042

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Empirical versus preemptive an ...... randomized, controlled trial.

@en

type

label

Empirical versus preemptive an ...... randomized, controlled trial.

@en

prefLabel

Empirical versus preemptive an ...... randomized, controlled trial.

@en

P1433

Q40395042-187B3154-F998-4DE8-B46A-F5C8F94536D1

P1476

Q40395042-6054BDC1-4F05-4899-9D9E-42EB80CDC60D

P2093

Q40395042-01BB7668-65D3-43FD-82AF-DA8AA5E97E54

Q40395042-200D4A30-B942-4A5A-9E3C-1C3F312DA1A6

Q40395042-53911B27-E503-49B7-BBFB-6A659580DFA7

Q40395042-752E012B-BA6B-4194-AC55-C817218307EE

Q40395042-8187FFDD-2EA1-494E-92B2-2DCFAD018B34

Q40395042-82FF30FE-A1D8-4DFE-9866-94D7728AC1F3

Q40395042-85FAB1C7-1178-42C4-BC8C-8D5910805F0A

Q40395042-8992D3E3-DB34-4C66-AA57-F8B2B47FA118

Q40395042-ADC2F9EC-6767-4132-9902-B6BDEA6849A0

Q40395042-AFC9C171-EB26-4385-B017-91B71263FBD3

P304

Q40395042-114E40CF-E2BF-45DC-8566-95DAD8D2B78A

P31

Q40395042-B89BD4CA-289F-480B-AB2D-4A0F0DD88F1B

P356

Q40395042-F6B258F7-583E-43EB-92C7-9C951D6DFB57

P407

Q40395042-0CB98F2A-60FB-4078-A9FC-A89A15759716

P433

Q40395042-FF00F691-B1D4-478E-82F6-7D50E060A55D

P478

Q40395042-532C0967-217A-44FC-B6CA-06AD3B50FC60

P50

Q40395042-9A5082F0-6454-47E3-81BC-B02614572994

Q40395042-9A64F29E-E867-4DC3-8C47-2DB54044F5DD

P577

Q40395042-708FDECB-B728-48F7-86B8-109E12CEDD77

P5875

Q40395042-80995F24-1584-455A-9538-56C4F71463B9

P698

Q40395042-B740D094-986D-4790-9AB2-075F963B1DE8

P356

P1433

Clinical Infectious Diseases

P1476

Empirical versus preemptive an ...... a randomized, controlled trial

@en

P2093

Anne Vekhoff

http://www.w3.org/2001/XMLSchema#string

Catherine Cordonnier

http://www.w3.org/2001/XMLSchema#string

Cécile Pautas

http://www.w3.org/2001/XMLSchema#string

Felipe Suarez

http://www.w3.org/2001/XMLSchema#string

Francoise Isnard

http://www.w3.org/2001/XMLSchema#string

Françoise Foulet

http://www.w3.org/2001/XMLSchema#string

Frédérique Kuhnowski

http://www.w3.org/2001/XMLSchema#string

Hassan Farhat

http://www.w3.org/2001/XMLSchema#string

Lionel Ades

http://www.w3.org/2001/XMLSchema#string

Mathieu Kuentz

http://www.w3.org/2001/XMLSchema#string

P304

1042-1051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/597395

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Bretagne

Michael Schwarzinger

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24196230

http://www.w3.org/2001/XMLSchema#string

P698

19281327

http://www.w3.org/2001/XMLSchema#string